查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1854732

医用迴旋加速器市场：按应用、最终用户、迴旋加速器类型、产品和分销管道划分 - 全球预测（2025-2032 年）

Medical Cyclotron Market by Application, End User, Cyclotron Type, Product, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，医用迴旋加速器市场规模将达到 8.8731 亿美元，复合年增长率为 10.91%。

关键市场统计数据
基准年 2024 3.8735亿美元
预计年份：2025年 4.3056亿美元
预测年份 2032 8.8731亿美元
复合年增长率 (%) 10.91%

策略方向明确了医用迴旋加速器的临床作用、营运需求以及在现代放射性药物供应链中的整合。

医用迴旋加速器处于临床需求与工业能力的交会点，能够生产支撑现代诊断和治疗流程的短寿命放射性同位素。加速器设计、自动化和放射化学领域的最新进展缩短了生产週期，提高了局部同位素生产的可行性，并减少了对广泛分销网络的依赖。本文旨在为理解迴旋加速器技术如何与放射性药物工作流程、医院核子医学科和契约製造运作结合奠定基础。

此外，设施布局、屏蔽和法规遵循等营运因素也会影响资本规划和日常生产效率。以患者为中心的驱动因素，例如对精准诊断示踪剂和标靶治疗的需求，正在加速对能够与临床日程同步的灵活同位素生产的需求。因此，从医院管理者到製药研发人员等相关人员都在调整其采购和临床供应策略，以充分利用现代迴旋加速器部署所固有的营运优势。

本执行摘要探讨了重新定义迴旋加速器部署的技术、商业性和监管力量，重点关注可操作的见解，以支持采购决策、临床准备以及放射性药物生态系统中的伙伴关係。

技术创新、临床需求和不断演变的法律规范如何融合，从而重塑迴旋加速器的部署模式和运作策略？

受技术成熟、临床需求和不断变化的监管预期等因素的驱动，医用迴旋加速器领域正经历显着变革。紧凑型迴旋加速器架构和更高的能源效率拓展了其适用安装地点的范围，使影像中心和医院能够优先考虑现场生产而非集中供应模式。同时，标靶处理、放射化学模组和品管系统的自动化降低了对操作人员的依赖性，并提高了实验结果的可重复性。

同时，放射性药物价值链的垂直整合程度日益提高，製药公司和契约製造纷纷投资建立自有生产能力，以确保治疗和诊断示踪剂的持续供应。迴旋加速器原始设备製造商 (OEM) 与放射化学供应商之间的策略伙伴关係进一步促进了这种垂直整合，加速了技术转移并缩短了检验週期。法律规范也在适应新的生产模式。检查机构和认证机构正在更新其对设施资格确认、製程验证和无菌保证的要求，从而更加重视在计划早期规划阶段就纳入合规性设计。

总而言之，这些转变体现了技术能力、临床需求和监管要求的融合，有利于可快速扩展和验证的适应性强的迴旋加速器解决方案。最终结果是风险和机会的重新分配：临床机构对其同位素供应拥有更大的控制权，而製造商和服务供应商必须证明其稳定性和合规性，才能赢得长期合作关係。

了解近期关税驱动的贸易政策转变如何改变迴旋加速器基础设施的采购经济、供应链韧性和售后市场支持。

近期贸易政策调整引发的关税措施，为迴旋加速器系统及配套设备的采购与供应带来了显着的复杂动态。影响进口零件、精密加工和部分电子子系统的关税提高了到岸成本，奖励供应商重新评估其全球生产布局。这使得采购负责人更加关注总体拥有成本分析，该分析涵盖关税、跨境物流和潜在的前置作业时间变化。

在供应商层面，製造商正透过供应商多元化、组装以及在某些情况下与区域性加工商合作来应对关税影响。这些策略性措施有助于保护净利率并维持价格竞争力，但同时也为从新的司法管辖区采购零件时的品管和监管文件带来了挑战。对于医院和诊断影像中心的采购者而言，关税环境也促使他们考虑基于服务的安排和租赁模式，这些模式可以平滑资本支出并将某些外汇和贸易风险转移给供应商。

在营运层面，关税会对备件供应和售后服务合约产生下游影响。使用旧有系统的设施可能会面临更长的更换零件采购週期，从而增加成本。此外，目前的贸易环境预示着供应链中断的风险，并凸显了包含价格上涨条款、优先采购选项以及买卖双方风险共担机制的稳健合约条款的重要性。最终，贸易政策的转变迫使相关人员采取更具韧性的筹资策略，并投资于能够平衡成本控制、确保品质和业务连续性的合作关係。

将应用需求、最终用户画像、迴旋加速器能量等级、产品架构和通路与采购和营运优先顺序相匹配的可操作细分智能

透过精细的細項分析，可以揭示不同应用领域、最终用户、迴旋加速器类型、产品架构和通路的需求驱动因素和采购行为的差异。依应用领域划分，生产分为放射性药物生产和科研应用，放射性药物生产可进一步细分为诊断示踪剂和治疗性放射性同位素，二者在产量、品质和监管要求方面各有不同。最终用户包括诊断影像中心、医院、製药公司和研究机构，它们各自拥有不同的资金限制、合规要求和营运优先级，这些因素决定了它们偏好的合约类型和服务水准。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 促进自动化放射性药物工作流程与迴旋加速器系统的集成，提高处理效率和合规性。
  • 标靶技术的进步提高了新型放射性金属在诊疗整合应用的产量。
  • 采用远端监控和预测性维护工具，最大限度地减少迴旋加速器停机时间和故障。
  • 开发超紧凑型高能量迴旋加速器，以便在小型研究医院进行现场生产。
  • 世界各地区为简化迴旋加速器安装核准而进行的监理协调工作
  • 神经影像学和肿瘤诊断市场的扩张将推动对碳-11和氟-18的需求。
  • 迴旋加速器製造商与製药公司结成策略联盟，旨在推动新型放射性示踪剂研发。
  • 迴旋加速器设施正在转型采用节能型冷却和电力系统，以降低营运成本和占地面积。
  • 增加对迴旋加速器基础设施的投资，以实现新兴市场放射性药物供应网络的去中心化。
  • 人工智慧驱动的製程优化技术的整合提高了迴旋加速器运行中同位素生产的产量和品管。

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 按应用程式分類的医用迴旋加速器市场

  • 放射性药物生产
    • 诊断追踪器
    • 治疗性放射性同位素
  • 研究用途

第九章 依最终用户分類的医用迴旋加速器市场

  • 诊断影像中心
  • 医院
  • 製药公司
  • 研究所

第十章 医用迴旋加速器市场（依迴旋加速器型划分）

  • 高能量
  • 低能耗
  • 中等能量

第十一章 医用迴旋加速器市场（依产品分类）

  • 双迴旋加速器
  • 单迴旋加速器

第十二章 医用迴旋加速器市场（依通路划分）

  • 通路伙伴
  • 直销

第十三章 区域性医用迴旋加速器市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 医用迴旋加速器市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国医用迴旋加速器市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Ion Beam Applications SA
    • Sumitomo Heavy Industries, Ltd.
    • Siemens Healthineers AG
    • Advanced Cyclotron Systems Inc.
    • Best Theratronics Limited
    • Shimadzu Corporation
    • ACCEL Instruments GmbH
    • Huayi Isotope Co., Ltd.
    • EBARA Corporation
    • Niowave, Inc.
Product Code: MRR-957C47F92F8F

The Medical Cyclotron Market is projected to grow by USD 887.31 million at a CAGR of 10.91% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 387.35 million
Estimated Year [2025] USD 430.56 million
Forecast Year [2032] USD 887.31 million
CAGR (%) 10.91%

A strategic orientation to medical cyclotrons that clarifies their clinical roles, operational demands, and integration into contemporary radiopharmaceutical supply chains

The medical cyclotron sits at the intersection of clinical need and industrial capability, enabling the production of short lived radioisotopes that underpin contemporary diagnostic and therapeutic pathways. In recent years, advances in accelerator design, automation, and radiochemistry have shortened production cycles and increased the feasibility of localised isotope manufacture, shifting reliance away from extended distribution networks. This introduction sets the stage for understanding how cyclotron technologies integrate with radiopharmaceutical workflows, hospital nuclear medicine departments, and contract manufacturing operations.

Moreover, operational considerations such as facility siting, shielding and regulatory compliance shape both capital planning and day to day throughput. Patient centric drivers, including demands for precise diagnostic tracers and targeted therapeutics, create an accelerating need for flexible isotope production that can be synchronized with clinical schedules. Consequently, stakeholders from hospital administrators to pharmaceutical developers are recalibrating procurement and clinical supply strategies to capture the operational benefits inherent in modern cyclotron deployments.

The remainder of this executive summary explores the technical, commercial, and regulatory forces that are redefining cyclotron adoption, with an emphasis on pragmatic insights that support procurement decisions, clinical readiness, and partnerships across the radiopharmaceutical ecosystem.

How technological innovations, clinical demand, and evolving regulatory frameworks are converging to reshape cyclotron deployment models and operational strategies

The landscape for medical cyclotrons is experiencing transformative shifts driven by technological maturation, clinical demand, and evolving regulatory expectations. Improvements in compact cyclotron architecture and energy efficiency have broadened the range of viable installation sites, enabling diagnostic imaging centers and hospitals to weigh on site production against centralized supply models. Concurrently, automation of target handling, radiochemistry modules, and quality control systems is reducing operator dependency and enhancing reproducibility, which in turn supports multi shift operations and higher throughput.

At the same time, the radiopharmaceutical value chain is becoming more vertically integrated, with pharmaceutical companies and contract manufacturers investing in in house production capabilities to secure supply continuity for therapeutic and diagnostic tracers. This verticalization is complemented by strategic partnerships between cyclotron OEMs and radiochemistry vendors that accelerate technology transfer and shorten validation cycles. Regulatory frameworks are also adapting to new production paradigms; inspectors and certifying bodies are updating expectations for facility qualification, process validation, and sterility assurance, which increases the importance of design for compliance during early project planning.

Taken together, these shifts create an environment where technological capability, clinical need, and regulatory alignment converge to favor adaptable cyclotron solutions that can be scaled and validated rapidly. The net effect is a redistribution of risk and opportunity: clinical sites gain more control over their isotopic supply while manufacturers and service providers must demonstrate consistency and compliance to capture long term collaborations.

Understanding how recent tariff driven trade policy shifts are altering procurement economics, supply chain resilience, and aftermarket support for cyclotron infrastructure

Recent tariff actions originating in trade policy adjustments have introduced measurable complexity into the procurement and supply dynamics for cyclotron systems and ancillary equipment. Tariffs that affect imported components, precision machining, and select electronic subsystems have increased the landed cost and created incentives for suppliers to reassess their global manufacturing footprints. For procurement professionals, this has translated into a renewed focus on total cost of ownership analyses that incorporate customs duties, cross border logistics, and potential lead time variability.

At the supplier level, manufacturers are responding by diversifying suppliers, localizing assembly, and in some cases initiating partner agreements with regional fabricators to mitigate tariff exposure. These strategic moves help preserve margin and maintain competitive pricing but also introduce challenges related to quality control and regulatory documentation when components are sourced from new jurisdictions. For hospital and imaging center purchasers, the tariff environment has also encouraged exploration of service based arrangements and leasing models that can smooth capital expenditures and transfer certain currency and trade risks to vendors.

Operationally, tariffs have a downstream effect on spare parts availability and aftermarket service contracts. Facilities that operate legacy systems may encounter longer procurement cycles and higher costs for replacement parts, which in turn elevates the importance of preventive maintenance and inventory planning. In addition, the current trade landscape underscores the value of robust contractual terms that anticipate supply chain disruption and embed escalation clauses, preferential procurement options, and collaborative risk sharing between buyers and suppliers. Ultimately, trade policy shifts are compelling stakeholders to adopt more resilient sourcing strategies and to invest in relationships that balance cost control with assurances of quality and continuity.

Actionable segmentation intelligence that aligns application needs, end user profiles, cyclotron energy classes, product architectures, and distribution pathways with procurement and operational priorities

A refined segmentation lens reveals differentiated demand drivers and procurement behaviours across application, end user, cyclotron type, product architecture, and distribution channel. Based on Application, production is bifurcated into radiopharmaceutical production and research applications, with radiopharmaceutical production further divided into diagnostic tracers and therapeutic radioisotopes, which drive divergent throughput, quality and regulatory needs. Based on End User, the landscape includes diagnostic imaging centers, hospitals, pharmaceutical companies, and research institutes, each with unique capital constraints, compliance requirements, and operational priorities that dictate preferred contract structures and service levels.

Based on Cyclotron Type, the selection among high energy, medium energy, and low energy platforms reflects the isotopic portfolio targeted by the operator and the scale of production required. High energy systems enable a broader array of radioisotopes suitable for therapeutic applications, whereas low and medium energy systems are frequently optimized for routine diagnostic tracer manufacturing. Based on Product, procurement choices span single cyclotron deployments where capacity and cost efficiency are paramount versus dual cyclotron configurations that provide redundancy and increased scheduling flexibility, which is particularly important for high throughput clinical environments.

Finally, based on Distribution Channel, sales activity is channelled through direct sales relationships and channel partners, with direct sales often preferred for bespoke installations requiring extensive integration and local partnership coordination, while channel partners can accelerate market entry and provide localized service capabilities. Recognizing these segment distinctions helps stakeholders align technology selection, contractual design, and operational planning with their strategic objectives, thereby reducing implementation friction and improving service reliability.

Regional strategic considerations that reconcile regulatory diversity, clinical demand growth, and localized manufacturing capacity across major global markets

Regional dynamics exert a profound influence on infrastructure adoption, regulatory approach, and supply chain configuration across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, investment in localized production capacity is driven by dense clinical networks and an emphasis on reducing distribution lead times for short lived isotopes; capital availability and established regulatory pathways often facilitate rapid facility qualification. By contrast, the Europe, Middle East & Africa region presents a mosaic of regulatory regimes and reimbursement environments, where cross border collaboration and centralized manufacturing models remain important for cost efficiency and specialist isotope supply.

Asia-Pacific is characterized by rapidly expanding clinical demand, government initiatives to build domestic radiopharmaceutical capabilities, and a growing base of domestic equipment manufacturers that are enhancing regional supply security. Across regions, differences in workforce skill sets, radiation protection standards, and infrastructure funding mechanisms dictate tailored approaches to training, facility design, and long term service contracts. For multinational suppliers, these regional distinctions necessitate flexible business models that can accommodate localized regulatory documentation, regional partners for maintenance and qualification, and adaptive pricing strategies aligned with purchasing power and reimbursement frameworks.

Taken together, geographic nuance informs where investments in redundancy, local inventory, and regional centers of excellence will yield the greatest resilience and clinical impact. Transitioning from global templates to region specific strategies reduces deployment friction and accelerates time to clinical integration.

Competitive and partnership dynamics that shape supplier selection, after sales support models, and strategic alliances across the cyclotron and radiochemistry ecosystem

Competitive dynamics in the cyclotron ecosystem are shaped by a mix of established original equipment manufacturers, specialist radiochemistry suppliers, contract manufacturing organizations, and service integrators that together form an interdependent commercial network. Established OEMs compete on reliability, legacy installed base support, and engineering services, while newer entrants differentiate through compact designs, automation, and cost effective service models. Radiochemistry vendors and module providers play a critical role in turnkey solutions, enabling faster validation and compliance for clinical tracer production.

Partnerships and strategic alliances are common, with OEMs collaborating with radiopharmaceutical developers to co validate isotope production pathways and with service providers to offer managed production contracts. Similarly, contract development and manufacturing organizations expand access to therapeutic isotopes by providing GMP compliant suites and validated radiochemistry workflows that reduce the entry barrier for smaller pharmaceutical developers. Service models are evolving from reactive maintenance to predictive and subscription based support, leveraging remote diagnostics and telemetry to minimize downtime and extend equipment life.

For buyers evaluating suppliers, differentiation should be assessed across four dimensions: engineering robustness and uptime performance; depth of regulatory and quality documentation support; aftermarket service coverage and spare part logistics; and the supplier's ability to support process transfer for both diagnostic and therapeutic isotopes. These criteria guide procurement to partners that can de risk implementation, accelerate clinical readiness, and provide long term operational assurance.

Actionable operational and procurement recommendations that optimize facility design, service arrangements, workforce capability, and supply chain resilience for cyclotron deployments

Industry leaders must adopt pragmatic, forward looking actions to capture clinical value while mitigating operational risk. First, prioritize integration planning that aligns facility design with regulatory expectations and clinical scheduling, including early engagement with radiation safety officers and quality teams to streamline qualification. Second, favor modular and upgradeable cyclotron architectures that permit phased investment, enabling organizations to scale isotopic capabilities as clinical demand evolves without incurring prohibitive early capital commitments.

Third, negotiate service arrangements that include defined response times, critical spare inventories, and options for remote monitoring to preserve uptime. Fourth, pursue collaborative procurement and shared supply models among regional clinical networks to optimize utilization and reduce per unit production costs while maintaining compliance. Fifth, invest in workforce development and cross functional training across operations, radiochemistry, and quality assurance to sustain consistent production and regulatory readiness.

Finally, incorporate scenario based supply chain planning that tests the resilience of sourcing options and identifies critical single points of failure. By executing these recommendations, industry participants can reduce implementation friction, strengthen supply continuity, and position themselves to respond rapidly to evolving clinical needs and regulatory expectations.

A rigorous multi method research approach that integrates stakeholder interviews, technical literature, and case based validation to produce actionable and reproducible insights

The research synthesis that informs this executive summary combined qualitative expert interviews, technical literature review, and primary engagement with equipment designers, clinical operators, and radiopharmaceutical developers. Interviews were conducted with a cross section of stakeholders to capture operational experience, procurement decision criteria, and regulatory pain points. Technical literature and regulatory guidance documents were reviewed to validate engineering constraints, validation expectations, and radiation protection standards.

Analytical methods emphasized triangulation: qualitative insights from interviews were cross referenced with documented regulatory requirements and vendor technical specifications to ensure coherence. Case studies of recent installations were examined to extract best practices in facility layout, shielding design, and radiochemistry workflow integration. Sensitivity checks were applied to assumptions about lead times, service coverage, and component sourcing to identify key risk vectors affecting deployment and continuity.

Throughout the methodology, emphasis was placed on reproducibility and traceability of findings. Data sources and interview protocols were selected to provide balanced perspectives across clinical, commercial, and regulatory domains, and conclusions were tempered to reflect operational realities rather than hypothetical constructs. The approach privileges actionable insight and pragmatic guidance to support decision makers in procurement, clinical operations, and strategic planning roles.

Concluding synthesis that reframes cyclotron investment as a strategic capability enabling clinical innovation, supply resilience, and operational excellence

In conclusion, medical cyclotron deployment represents a strategic capability that aligns clinical demand for advanced diagnostics and therapeutics with an increasingly sophisticated manufacturing and regulatory environment. Technological advances have expanded where and how isotopes can be produced, while trade policy and procurement considerations require more nuanced sourcing strategies. Successful adoption depends on integrating facility design, regulatory planning, workforce development, and durable supplier relationships to ensure consistent clinical supply.

Decision makers should view cyclotron investments not only as capital purchases but as anchors for broader radiopharmaceutical strategy, enabling local innovation, improving patient access, and creating operational resilience. By following the evidence based recommendations outlined here-emphasizing modular design, robust service agreements, collaborative procurement, and workforce training-organizations can reduce implementation risk and accelerate clinical benefit delivery.

This executive summary provides a foundation for deeper engagement with the detailed report, which contains implementation checklists, technical annexes, and supplier evaluation frameworks to support procurement and operational teams as they translate strategy into practice.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Increasing integration of automated radiopharmacy workflows with cyclotron systems to boost throughput and compliance
  • 5.2. Emergence of solid targetry advancements enhancing yield of novel radiometals for theranostic applications
  • 5.3. Adoption of remote monitoring and predictive maintenance tools for minimizing cyclotron downtime and errors
  • 5.4. Development of ultra-compact high-energy cyclotrons enabling on-site production in small research hospitals
  • 5.5. Regulatory harmonization efforts streamlining cyclotron installation approvals across different global regions
  • 5.6. Demand growth for carbon-11 and fluorine-18 driven by expanding market for neuroimaging and oncology diagnostics
  • 5.7. Strategic partnerships between cyclotron manufacturers and pharmaceutical companies targeting novel radiotracer pipelines
  • 5.8. Shift towards energy-efficient cooling and power systems in cyclotron facilities to reduce operational costs and footprint
  • 5.9. Rising investments in cyclotron infrastructure within emerging markets to decentralize radiopharmaceutical supply networks
  • 5.10. Integration of AI-driven process optimization to enhance isotope production yield and quality control in cyclotron operations

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Medical Cyclotron Market, by Application

  • 8.1. Radiopharmaceutical Production
    • 8.1.1. Diagnostic Tracers
    • 8.1.2. Therapeutic Radioisotopes
  • 8.2. Research Applications

9. Medical Cyclotron Market, by End User

  • 9.1. Diagnostic Imaging Centers
  • 9.2. Hospitals
  • 9.3. Pharmaceutical Companies
  • 9.4. Research Institutes

10. Medical Cyclotron Market, by Cyclotron Type

  • 10.1. High Energy
  • 10.2. Low Energy
  • 10.3. Medium Energy

11. Medical Cyclotron Market, by Product

  • 11.1. Dual Cyclotron
  • 11.2. Single Cyclotron

12. Medical Cyclotron Market, by Distribution Channel

  • 12.1. Channel Partners
  • 12.2. Direct Sales

13. Medical Cyclotron Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Medical Cyclotron Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Medical Cyclotron Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Ion Beam Applications S.A.
    • 16.3.2. Sumitomo Heavy Industries, Ltd.
    • 16.3.3. Siemens Healthineers AG
    • 16.3.4. Advanced Cyclotron Systems Inc.
    • 16.3.5. Best Theratronics Limited
    • 16.3.6. Shimadzu Corporation
    • 16.3.7. ACCEL Instruments GmbH
    • 16.3.8. Huayi Isotope Co., Ltd.
    • 16.3.9. EBARA Corporation
    • 16.3.10. Niowave, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL MEDICAL CYCLOTRON MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL MEDICAL CYCLOTRON MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL MEDICAL CYCLOTRON MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL MEDICAL CYCLOTRON MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL MEDICAL CYCLOTRON MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL MEDICAL CYCLOTRON MARKET SIZE, BY CYCLOTRON TYPE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL MEDICAL CYCLOTRON MARKET SIZE, BY CYCLOTRON TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL MEDICAL CYCLOTRON MARKET SIZE, BY PRODUCT, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL MEDICAL CYCLOTRON MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL MEDICAL CYCLOTRON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL MEDICAL CYCLOTRON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL MEDICAL CYCLOTRON MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS MEDICAL CYCLOTRON MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA MEDICAL CYCLOTRON MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA MEDICAL CYCLOTRON MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA MEDICAL CYCLOTRON MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE MEDICAL CYCLOTRON MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST MEDICAL CYCLOTRON MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA MEDICAL CYCLOTRON MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC MEDICAL CYCLOTRON MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL MEDICAL CYCLOTRON MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN MEDICAL CYCLOTRON MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC MEDICAL CYCLOTRON MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION MEDICAL CYCLOTRON MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS MEDICAL CYCLOTRON MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 MEDICAL CYCLOTRON MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO MEDICAL CYCLOTRON MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL MEDICAL CYCLOTRON MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. MEDICAL CYCLOTRON MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. MEDICAL CYCLOTRON MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. MEDICAL CYCLOTRON MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL MEDICAL CYCLOTRON MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL MEDICAL CYCLOTRON MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL MEDICAL CYCLOTRON MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL MEDICAL CYCLOTRON MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL MEDICAL CYCLOTRON MARKET SIZE, BY RADIOPHARMACEUTICAL PRODUCTION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL MEDICAL CYCLOTRON MARKET SIZE, BY RADIOPHARMACEUTICAL PRODUCTION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL MEDICAL CYCLOTRON MARKET SIZE, BY RADIOPHARMACEUTICAL PRODUCTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL MEDICAL CYCLOTRON MARKET SIZE, BY RADIOPHARMACEUTICAL PRODUCTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL MEDICAL CYCLOTRON MARKET SIZE, BY RADIOPHARMACEUTICAL PRODUCTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL MEDICAL CYCLOTRON MARKET SIZE, BY RADIOPHARMACEUTICAL PRODUCTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL MEDICAL CYCLOTRON MARKET SIZE, BY RADIOPHARMACEUTICAL PRODUCTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL MEDICAL CYCLOTRON MARKET SIZE, BY RADIOPHARMACEUTICAL PRODUCTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL MEDICAL CYCLOTRON MARKET SIZE, BY DIAGNOSTIC TRACERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL MEDICAL CYCLOTRON MARKET SIZE, BY DIAGNOSTIC TRACERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL MEDICAL CYCLOTRON MARKET SIZE, BY DIAGNOSTIC TRACERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL MEDICAL CYCLOTRON MARKET SIZE, BY DIAGNOSTIC TRACERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL MEDICAL CYCLOTRON MARKET SIZE, BY DIAGNOSTIC TRACERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL MEDICAL CYCLOTRON MARKET SIZE, BY DIAGNOSTIC TRACERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL MEDICAL CYCLOTRON MARKET SIZE, BY THERAPEUTIC RADIOISOTOPES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL MEDICAL CYCLOTRON MARKET SIZE, BY THERAPEUTIC RADIOISOTOPES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL MEDICAL CYCLOTRON MARKET SIZE, BY THERAPEUTIC RADIOISOTOPES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL MEDICAL CYCLOTRON MARKET SIZE, BY THERAPEUTIC RADIOISOTOPES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL MEDICAL CYCLOTRON MARKET SIZE, BY THERAPEUTIC RADIOISOTOPES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL MEDICAL CYCLOTRON MARKET SIZE, BY THERAPEUTIC RADIOISOTOPES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL MEDICAL CYCLOTRON MARKET SIZE, BY RESEARCH APPLICATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL MEDICAL CYCLOTRON MARKET SIZE, BY RESEARCH APPLICATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL MEDICAL CYCLOTRON MARKET SIZE, BY RESEARCH APPLICATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL MEDICAL CYCLOTRON MARKET SIZE, BY RESEARCH APPLICATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL MEDICAL CYCLOTRON MARKET SIZE, BY RESEARCH APPLICATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL MEDICAL CYCLOTRON MARKET SIZE, BY RESEARCH APPLICATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL MEDICAL CYCLOTRON MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL MEDICAL CYCLOTRON MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL MEDICAL CYCLOTRON MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL MEDICAL CYCLOTRON MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL MEDICAL CYCLOTRON MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL MEDICAL CYCLOTRON MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL MEDICAL CYCLOTRON MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL MEDICAL CYCLOTRON MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL MEDICAL CYCLOTRON MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL MEDICAL CYCLOTRON MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL MEDICAL CYCLOTRON MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL MEDICAL CYCLOTRON MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL MEDICAL CYCLOTRON MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL MEDICAL CYCLOTRON MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL MEDICAL CYCLOTRON MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL MEDICAL CYCLOTRON MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL MEDICAL CYCLOTRON MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL MEDICAL CYCLOTRON MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL MEDICAL CYCLOTRON MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL MEDICAL CYCLOTRON MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL MEDICAL CYCLOTRON MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL MEDICAL CYCLOTRON MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL MEDICAL CYCLOTRON MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL MEDICAL CYCLOTRON MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL MEDICAL CYCLOTRON MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL MEDICAL CYCLOTRON MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL MEDICAL CYCLOTRON MARKET SIZE, BY CYCLOTRON TYPE, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL MEDICAL CYCLOTRON MARKET SIZE, BY CYCLOTRON TYPE, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL MEDICAL CYCLOTRON MARKET SIZE, BY HIGH ENERGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL MEDICAL CYCLOTRON MARKET SIZE, BY HIGH ENERGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL MEDICAL CYCLOTRON MARKET SIZE, BY HIGH ENERGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL MEDICAL CYCLOTRON MARKET SIZE, BY HIGH ENERGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL MEDICAL CYCLOTRON MARKET SIZE, BY HIGH ENERGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL MEDICAL CYCLOTRON MARKET SIZE, BY HIGH ENERGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL MEDICAL CYCLOTRON MARKET SIZE, BY LOW ENERGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL MEDICAL CYCLOTRON MARKET SIZE, BY LOW ENERGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL MEDICAL CYCLOTRON MARKET SIZE, BY LOW ENERGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL MEDICAL CYCLOTRON MARKET SIZE, BY LOW ENERGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL MEDICAL CYCLOTRON MARKET SIZE, BY LOW ENERGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL MEDICAL CYCLOTRON MARKET SIZE, BY LOW ENERGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL MEDICAL CYCLOTRON MARKET SIZE, BY MEDIUM ENERGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL MEDICAL CYCLOTRON MARKET SIZE, BY MEDIUM ENERGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL MEDICAL CYCLOTRON MARKET SIZE, BY MEDIUM ENERGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL MEDICAL CYCLOTRON MARKET SIZE, BY MEDIUM ENERGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL MEDICAL CYCLOTRON MARKET SIZE, BY MEDIUM ENERGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL MEDICAL CYCLOTRON MARKET SIZE, BY MEDIUM ENERGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL MEDICAL CYCLOTRON MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL MEDICAL CYCLOTRON MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL MEDICAL CYCLOTRON MARKET SIZE, BY DUAL CYCLOTRON, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL MEDICAL CYCLOTRON MARKET SIZE, BY DUAL CYCLOTRON, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL MEDICAL CYCLOTRON MARKET SIZE, BY DUAL CYCLOTRON, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL MEDICAL CYCLOTRON MARKET SIZE, BY DUAL CYCLOTRON, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL MEDICAL CYCLOTRON MARKET SIZE, BY DUAL CYCLOTRON, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL MEDICAL CYCLOTRON MARKET SIZE, BY DUAL CYCLOTRON, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL MEDICAL CYCLOTRON MARKET SIZE, BY SINGLE CYCLOTRON, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL MEDICAL CYCLOTRON MARKET SIZE, BY SINGLE CYCLOTRON, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL MEDICAL CYCLOTRON MARKET SIZE, BY SINGLE CYCLOTRON, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL MEDICAL CYCLOTRON MARKET SIZE, BY SINGLE CYCLOTRON, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL MEDICAL CYCLOTRON MARKET SIZE, BY SINGLE CYCLOTRON, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL MEDICAL CYCLOTRON MARKET SIZE, BY SINGLE CYCLOTRON, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL MEDICAL CYCLOTRON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL MEDICAL CYCLOTRON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL MEDICAL CYCLOTRON MARKET SIZE, BY CHANNEL PARTNERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL MEDICAL CYCLOTRON MARKET SIZE, BY CHANNEL PARTNERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL MEDICAL CYCLOTRON MARKET SIZE, BY CHANNEL PARTNERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL MEDICAL CYCLOTRON MARKET SIZE, BY CHANNEL PARTNERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL MEDICAL CYCLOTRON MARKET SIZE, BY CHANNEL PARTNERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL MEDICAL CYCLOTRON MARKET SIZE, BY CHANNEL PARTNERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL MEDICAL CYCLOTRON MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL MEDICAL CYCLOTRON MARKET SIZE, BY DIRECT SALES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL MEDICAL CYCLOTRON MARKET SIZE, BY DIRECT SALES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL MEDICAL CYCLOTRON MARKET SIZE, BY DIRECT SALES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL MEDICAL CYCLOTRON MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL MEDICAL CYCLOTRON MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL MEDICAL CYCLOTRON MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL MEDICAL CYCLOTRON MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. AMERICAS MEDICAL CYCLOTRON MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 110. AMERICAS MEDICAL CYCLOTRON MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 111. AMERICAS MEDICAL CYCLOTRON MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 112. AMERICAS MEDICAL CYCLOTRON MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 113. AMERICAS MEDICAL CYCLOTRON MARKET SIZE, BY RADIOPHARMACEUTICAL PRODUCTION, 2018-2024 (USD MILLION)
  • TABLE 114. AMERICAS MEDICAL CYCLOTRON MARKET SIZE, BY RADIOPHARMACEUTICAL PRODUCTION, 2025-2032 (USD MILLION)
  • TABLE 115. AMERICAS MEDICAL CYCLOTRON MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 116. AMERICAS MEDICAL CYCLOTRON MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 117. AMERICAS MEDICAL CYCLOTRON MARKET SIZE, BY CYCLOTRON TYPE, 2018-2024 (USD MILLION)
  • TABLE 118. AMERICAS MEDICAL CYCLOTRON MARKET SIZE, BY CYCLOTRON TYPE, 2025-2032 (USD MILLION)
  • TABLE 119. AMERICAS MEDICAL CYCLOTRON MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 120. AMERICAS MEDICAL CYCLOTRON MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 121. AMERICAS MEDICAL CYCLOTRON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 122. AMERICAS MEDICAL CYCLOTRON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA MEDICAL CYCLOTRON MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. NORTH AMERICA MEDICAL CYCLOTRON MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA MEDICAL CYCLOTRON MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 126. NORTH AMERICA MEDICAL CYCLOTRON MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA MEDICAL CYCLOTRON MARKET SIZE, BY RADIOPHARMACEUTICAL PRODUCTION, 2018-2024 (USD MILLION)
  • TABLE 128. NORTH AMERICA MEDICAL CYCLOTRON MARKET SIZE, BY RADIOPHARMACEUTICAL PRODUCTION, 2025-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA MEDICAL CYCLOTRON MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 130. NORTH AMERICA MEDICAL CYCLOTRON MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA MEDICAL CYCLOTRON MARKET SIZE, BY CYCLOTRON TYPE, 2018-2024 (USD MILLION)
  • TABLE 132. NORTH AMERICA MEDICAL CYCLOTRON MARKET SIZE, BY CYCLOTRON TYPE, 2025-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA MEDICAL CYCLOTRON MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 134. NORTH AMERICA MEDICAL CYCLOTRON MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA MEDICAL CYCLOTRON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 136. NORTH AMERICA MEDICAL CYCLOTRON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA MEDICAL CYCLOTRON MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. LATIN AMERICA MEDICAL CYCLOTRON MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA MEDICAL CYCLOTRON MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 140. LATIN AMERICA MEDICAL CYCLOTRON MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA MEDICAL CYCLOTRON MARKET SIZE, BY RADIOPHARMACEUTICAL PRODUCTION, 2018-2024 (USD MILLION)
  • TABLE 142. LATIN AMERICA MEDICAL CYCLOTRON MARKET SIZE, BY RADIOPHARMACEUTICAL PRODUCTION, 2025-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA MEDICAL CYCLOTRON MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 144. LATIN AMERICA MEDICAL CYCLOTRON MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA MEDICAL CYCLOTRON MARKET SIZE, BY CYCLOTRON TYPE, 2018-2024 (USD MILLION)
  • TABLE 146. LATIN AMERICA MEDICAL CYCLOTRON MARKET SIZE, BY CYCLOTRON TYPE, 2025-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA MEDICAL CYCLOTRON MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 148. LATIN AMERICA MEDICAL CYCLOTRON MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA MEDICAL CYCLOTRON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 150. LATIN AMERICA MEDICAL CYCLOTRON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA MEDICAL CYCLOTRON MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA MEDICAL CYCLOTRON MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA MEDICAL CYCLOTRON MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA MEDICAL CYCLOTRON MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA MEDICAL CYCLOTRON MARKET SIZE, BY RADIOPHARMACEUTICAL PRODUCTION, 2018-2024 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA MEDICAL CYCLOTRON MARKET SIZE, BY RADIOPHARMACEUTICAL PRODUCTION, 2025-2032 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA MEDICAL CYCLOTRON MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA MEDICAL CYCLOTRON MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA MEDICAL CYCLOTRON MARKET SIZE, BY CYCLOTRON TYPE, 2018-2024 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA MEDICAL CYCLOTRON MARKET SIZE, BY CYCLOTRON TYPE, 2025-2032 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA MEDICAL CYCLOTRON MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA MEDICAL CYCLOTRON MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 163. EUROPE, MIDDLE EAST & AFRICA MEDICAL CYCLOTRON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 164. EUROPE, MIDDLE EAST & AFRICA MEDICAL CYCLOTRON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 165. EUROPE MEDICAL CYCLOTRON MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. EUROPE MEDICAL CYCLOTRON MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. EUROPE MEDICAL CYCLOTRON MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 168. EUROPE MEDICAL CYCLOTRON MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 169. EUROPE MEDICAL CYCLOTRON MARKET SIZE, BY RADIOPHARMACEUTICAL PRODUCTION, 2018-2024 (USD MILLION)
  • TABLE 170. EUROPE MEDICAL CYCLOTRON MARKET SIZE, BY RADIOPHARMACEUTICAL PRODUCTION, 2025-2032 (USD MILLION)
  • TABLE 171. EUROPE MEDICAL CYCLOTRON MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 172. EUROPE MEDICAL CYCLOTRON MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 173. EUROPE MEDICAL CYCLOTRON MARKET SIZE, BY CYCLOTRON TYPE, 2018-2024 (USD MILLION)
  • TABLE 174. EUROPE MEDICAL CYCLOTRON MARKET SIZE, BY CYCLOTRON TYPE, 2025-2032 (USD MILLION)
  • TABLE 175. EUROPE MEDICAL CYCLOTRON MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 176. EUROPE MEDICAL CYCLOTRON MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 177. EUROPE MEDICAL CYCLOTRON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 178. EUROPE MEDICAL CYCLOTRON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 179. MIDDLE EAST MEDICAL CYCLOTRON MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. MIDDLE EAST MEDICAL CYCLOTRON MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. MIDDLE EAST MEDICAL CYCLOTRON MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 182. MIDDLE EAST MEDICAL CYCLOTRON MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 183. MIDDLE EAST MEDICAL CYCLOTRON MARKET SIZE, BY RADIOPHARMACEUTICAL PRODUCTION, 2018-2024 (USD MILLION)
  • TABLE 184. MIDDLE EAST MEDICAL CYCLOTRON MARKET SIZE, BY RADIOPHARMACEUTICAL PRODUCTION, 2025-2032 (USD MILLION)
  • TABLE 185. MIDDLE EAST MEDICAL CYCLOTRON MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 186. MIDDLE EAST MEDICAL CYCLOTRON MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 187. MIDDLE EAST MEDICAL CYCLOTRON MARKET SIZE, BY CYCLOTRON TYPE, 2018-2024 (USD MILLION)
  • TABLE 188. MIDDLE EAST MEDICAL CYCLOTRON MARKET SIZE, BY CYCLOTRON TYPE, 2025-2032 (USD MILLION)
  • TABLE 189. MIDDLE EAST MEDICAL CYCLOTRON MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 190. MIDDLE EAST MEDICAL CYCLOTRON MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST MEDICAL CYCLOTRON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 192. MIDDLE EAST MEDICAL CYCLOTRON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 193. AFRICA MEDICAL CYCLOTRON MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. AFRICA MEDICAL CYCLOTRON MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. AFRICA MEDICAL CYCLOTRON MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 196. AFRICA MEDICAL CYCLOTRON MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 197. AFRICA MEDICAL CYCLOTRON MARKET SIZE, BY RADIOPHARMACEUTICAL PRODUCTION, 2018-2024 (USD MILLION)
  • TABLE 198. AFRICA MEDICAL CYCLOTRON MARKET SIZE, BY RADIOPHARMACEUTICAL PRODUCTION, 2025-2032 (USD MILLION)
  • TABLE 199. AFRICA MEDICAL CYCLOTRON MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 200. AFRICA MEDICAL CYCLOTRON MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 201. AFRICA MEDICAL CYCLOTRON MARKET SIZE, BY CYCLOTRON TYPE, 2018-2024 (USD MILLION)
  • TABLE 202. AFRICA MEDICAL CYCLOTRON MARKET SIZE, BY CYCLOTRON TYPE, 2025-2032 (USD MILLION)
  • TABLE 203. AFRICA MEDICAL CYCLOTRON MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 204. AFRICA MEDICAL CYCLOTRON MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 205. AFRICA MEDICAL CYCLOTRON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 206. AFRICA MEDICAL CYCLOTRON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 207. ASIA-PACIFIC MEDICAL CYCLOTRON MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. ASIA-PACIFIC MEDICAL CYCLOTRON MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. ASIA-PACIFIC MEDICAL CYCLOTRON MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 210. ASIA-PACIFIC MEDICAL CYCLOTRON MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 211. ASIA-PACIFIC MEDICAL CYCLOTRON MARKET SIZE, BY RADIOPHARMACEUTICAL PRODUCTION, 2018-2024 (USD MILLION)
  • TABLE 212. ASIA-PACIFIC MEDICAL CYCLOTRON MARKET SIZE, BY RADIOPHARMACEUTICAL PRODUCTION, 2025-2032 (USD MILLION)
  • TABLE 213. ASIA-PACIFIC MEDICAL CYCLOTRON MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 214. ASIA-PACIFIC MEDICAL CYCLOTRON MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 215. ASIA-PACIFIC MEDICAL CYCLOTRON MARKET SIZE, BY CYCLOTRON TYPE, 2018-2024 (USD MILLION)
  • TABLE 216. ASIA-PACIFIC MEDICAL CYCLOTRON MARKET SIZE, BY CYCLOTRON TYPE, 2025-2032 (USD MILLION)
  • TABLE 217. ASIA-PACIFIC MEDICAL CYCLOTRON MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 218. ASIA-PACIFIC MEDICAL CYCLOTRON MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 219. ASIA-PACIFIC MEDICAL CYCLOTRON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 220. ASIA-PACIFIC MEDICAL CYCLOTRON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL MEDICAL CYCLOTRON MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL MEDICAL CYCLOTRON MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 223. ASEAN MEDICAL CYCLOTRON MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. ASEAN MEDICAL CYCLOTRON MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. ASEAN MEDICAL CYCLOTRON MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 226. ASEAN MEDICAL CYCLOTRON MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 227. ASEAN MEDICAL CYCLOTRON MARKET SIZE, BY RADIOPHARMACEUTICAL PRODUCTION, 2018-2024 (USD MILLION)
  • TABLE 228. ASEAN MEDICAL CYCLOTRON MARKET SIZE, BY RADIOPHARMACEUTICAL PRODUCTION, 2025-2032 (USD MILLION)
  • TABLE 229. ASEAN MEDICAL CYCLOTRON MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 230. ASEAN MEDICAL CYCLOTRON MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 231. ASEAN MEDICAL CYCLOTRON MARKET SIZE, BY CYCLOTRON TYPE, 2018-2024 (USD MILLION)
  • TABLE 232. ASEAN MEDICAL CYCLOTRON MARKET SIZE, BY CYCLOTRON TYPE, 2025-2032 (USD MILLION)
  • TABLE 233. ASEAN MEDICAL CYCLOTRON MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 234. ASEAN MEDICAL CYCLOTRON MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 235. ASEAN MEDICAL CYCLOTRON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 236. ASEAN MEDICAL CYCLOTRON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 237. GCC MEDICAL CYCLOTRON MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 238. GCC MEDICAL CYCLOTRON MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 239. GCC MEDICAL CYCLOTRON MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 240. GCC MEDICAL CYCLOTRON MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 241. GCC MEDICAL CYCLOTRON MARKET SIZE, BY RADIOPHARMACEUTICAL PRODUCTION, 2018-2024 (USD MILLION)
  • TABLE 242. GCC MEDICAL CYCLOTRON MARKET SIZE, BY RADIOPHARMACEUTICAL PRODUCTION, 2025-2032 (USD MILLION)
  • TABLE 243. GCC MEDICAL CYCLOTRON MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 244. GCC MEDICAL CYCLOTRON MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 245. GCC MEDICAL CYCLOTRON MARKET SIZE, BY CYCLOTRON TYPE, 2018-2024 (USD MILLION)
  • TABLE 246. GCC MEDICAL CYCLOTRON MARKET SIZE, BY CYCLOTRON TYPE, 2025-2032 (USD MILLION)
  • TABLE 247. GCC MEDICAL CYCLOTRON MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 248. GCC MEDICAL CYCLOTRON MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 249. GCC MEDICAL CYCLOTRON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 250. GCC MEDICAL CYCLOTRON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 251. EUROPEAN UNION MEDICAL CYCLOTRON MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPEAN UNION MEDICAL CYCLOTRON MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. EUROPEAN UNION MEDICAL CYCLOTRON MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPEAN UNION MEDICAL CYCLOTRON MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPEAN UNION MEDICAL CYCLOTRON MARKET SIZE, BY RADIOPHARMACEUTICAL PRODUCTION, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPEAN UNION MEDICAL CYCLOTRON MARKET SIZE, BY RADIOPHARMACEUTICAL PRODUCTION, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPEAN UNION MEDICAL CYCLOTRON MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPEAN UNION MEDICAL CYCLOTRON MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPEAN UNION MEDICAL CYCLOTRON MARKET SIZE, BY CYCLOTRON TYPE, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPEAN UNION MEDICAL CYCLOTRON MARKET SIZE, BY CYCLOTRON TYPE, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPEAN UNION MEDICAL CYCLOTRON MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPEAN UNION MEDICAL CYCLOTRON MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPEAN UNION MEDICAL CYCLOTRON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPEAN UNION MEDICAL CYCLOTRON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 265. BRICS MEDICAL CYCLOTRON MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. BRICS MEDICAL CYCLOTRON MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. BRICS MEDICAL CYCLOTRON MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 268. BRICS MEDICAL CYCLOTRON MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 269. BRICS MEDICAL CYCLOTRON MARKET SIZE, BY RADIOPHARMACEUTICAL PRODUCTION, 2018-2024 (USD MILLION)
  • TABLE 270. BRICS MEDICAL CYCLOTRON MARKET SIZE, BY RADIOPHARMACEUTICAL PRODUCTION, 2025-2032 (USD MILLION)
  • TABLE 271. BRICS MEDICAL CYCLOTRON MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 272. BRICS MEDICAL CYCLOTRON MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 273. BRICS MEDICAL CYCLOTRON MARKET SIZE, BY CYCLOTRON TYPE, 2018-2024 (USD MILLION)
  • TABLE 274. BRICS MEDICAL CYCLOTRON MARKET SIZE, BY CYCLOTRON TYPE, 2025-2032 (USD MILLION)
  • TABLE 275. BRICS MEDICAL CYCLOTRON MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 276. BRICS MEDICAL CYCLOTRON MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 277. BRICS MEDICAL CYCLOTRON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 278. BRICS MEDICAL CYCLOTRON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 279. G7 MEDICAL CYCLOTRON MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 280. G7 MEDICAL CYCLOTRON MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 281. G7 MEDICAL CYCLOTRON MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 282. G7 MEDICAL CYCLOTRON MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 283. G7 MEDICAL CYCLOTRON MARKET SIZE, BY RADIOPHARMACEUTICAL PRODUCTION, 2018-2024 (USD MILLION)
  • TABLE 284. G7 MEDICAL CYCLOTRON MARKET SIZE, BY RADIOPHARMACEUTICAL PRODUCTION, 2025-2032 (USD MILLION)
  • TABLE 285. G7 MEDICAL CYCLOTRON MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 286. G7 MEDICAL CYCLOTRON MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 287. G7 MEDICAL CYCLOTRON MARKET SIZE, BY CYCLOTRON TYPE, 2018-2024 (USD MILLION)
  • TABLE 288. G7 MEDICAL CYCLOTRON MARKET SIZE, BY CYCLOTRON TYPE, 2025-2032 (USD MILLION)
  • TABLE 289. G7 MEDICAL CYCLOTRON MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 290. G7 MEDICAL CYCLOTRON MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 291. G7 MEDICAL CYCLOTRON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 292. G7 MEDICAL CYCLOTRON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 293. NATO MEDICAL CYCLOTRON MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 294. NATO MEDICAL CYCLOTRON MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 295. NATO MEDICAL CYCLOTRON MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 296. NATO MEDICAL CYCLOTRON MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 297. NATO MEDICAL CYCLOTRON MARKET SIZE, BY RADIOPHARMACEUTICAL PRODUCTION, 2018-2024 (USD MILLION)
  • TABLE 298. NATO MEDICAL CYCLOTRON MARKET SIZE, BY RADIOPHARMACEUTICAL PRODUCTION, 2025-2032 (USD MILLION)
  • TABLE 299. NATO MEDICAL CYCLOTRON MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 300. NATO MEDICAL CYCLOTRON MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 301. NATO MEDICAL CYCLOTRON MARKET SIZE, BY CYCLOTRON TYPE, 2018-2024 (USD MILLION)
  • TABLE 302. NATO MEDICAL CYCLOTRON MARKET SIZE, BY CYCLOTRON TYPE, 2025-2032 (USD MILLION)
  • TABLE 303. NATO MEDICAL CYCLOTRON MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 304. NATO MEDICAL CYCLOTRON MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 305. NATO MEDICAL CYCLOTRON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 306. NATO MEDICAL CYCLOTRON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 307. GLOBAL MEDICAL CYCLOTRON MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 308. GLOBAL MEDICAL CYCLOTRON MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 309. UNITED STATES MEDICAL CYCLOTRON MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 310. UNITED STATES MEDICAL CYCLOTRON MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 311. UNITED STATES MEDICAL CYCLOTRON MARKET SIZE, BY RADIOPHARMACEUTICAL PRODUCTION, 2018-2024 (USD MILLION)
  • TABLE 312. UNITED STATES MEDICAL CYCLOTRON MARKET SIZE, BY RADIOPHARMACEUTICAL PRODUCTION, 2025-2032 (USD MILLION)
  • TABLE 313. UNITED STATES MEDICAL CYCLOTRON MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 314. UNITED STATES MEDICAL CYCLOTRON MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 315. UNITED STATES MEDICAL CYCLOTRON MARKET SIZE, BY CYCLOTRON TYPE, 2018-2024 (USD MILLION)
  • TABLE 316. UNITED STATES MEDICAL CYCLOTRON MARKET SIZE, BY CYCLOTRON TYPE, 2025-2032 (USD MILLION)
  • TABLE 317. UNITED STATES MEDICAL CYCLOTRON MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 318. UNITED STATES MEDICAL CYCLOTRON MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 319. UNITED STATES MEDICAL CYCLOTRON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 320. UNITED STATES MEDICAL CYCLOTRON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 321. CANADA MEDICAL CYCLOTRON MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 322. CANADA MEDICAL CYCLOTRON MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 323. CANADA MEDICAL CYCLOTRON MARKET SIZE, BY RADIOPHARMACEUTICAL PRODUCTION, 2018-2024 (USD MILLION)
  • TABLE 324. CANADA MEDICAL CYCLOTRON MARKET SIZE, BY RADIOPHARMACEUTICAL PRODUCTION, 2025-2032 (USD MILLION)
  • TABLE 325. CANADA MEDICAL CYCLOTRON MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 326. CANADA MEDICAL CYCLOTRON MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 327. CANADA MEDICAL CYCLOTRON MARKET SIZE, BY CYCLOTRON TYPE, 2018-2024 (USD MILLION)
  • TABLE 328. CANADA MEDICAL CYCLOTRON MARKET SIZE, BY CYCLOTRON TYPE, 2025-2032 (USD MILLION)
  • TABLE 329. CANADA MEDICAL CYCLOTRON MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 330. CANADA MEDICAL CYCLOTRON MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 331. CANADA MEDICAL CYCLOTRON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 332. CANADA MEDICAL CYCLOTRON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 333. MEXICO MEDICAL CYCLOTRON MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 334. MEXICO MEDICAL CYCLOTRON MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 335. MEXICO MEDICAL CYCLOTRON MARKET SIZE, BY RADIOPHARMACEUTICAL PRODUCTION, 2018-2024 (USD MILLION)
  • TABLE 336. MEXICO MEDICAL CYCLOTRON MARKET SIZE, BY RADIOPHARMACEUTICAL PRODUCTION, 2025-2032 (USD MILLION)
  • TABLE 337. MEXICO MEDICAL CYCL